Published on January 24, 2026
Due to its strong commitment and scientific responsibility toward clients and their patients, UGA Biopharma considers state-of-the-art technological laboratories a fundamental requirement. Robust single-cell outgrowth and efficient development of stable CHO cell lines are essential standards we consistently uphold. Accordingly, UGA actively engages in testing and validating various technologies across multiple stages of development.
Recently, our Associate Scientist in Cell line Development Department, Ms. Dorothee Düsterhöft, evaluated InstiGRO® CHO CD in combination with UGA’s proprietary CHO Prime® media and feed platform, aiming to drive consistent single-cell outgrowth and robust cell line development performance.
